Key Takeaways
- Moderna (MRNA) stock gained approximately 9.8% over five trading sessions, closing at $250.83 on November 10 following stronger quarterly earnings and encouraging cancer treatment developments.
- Merck (MRK) and Moderna reported a 42% reduction in melanoma recurrence or death risk with their experimental cancer therapy combined with Keytruda.
- Pfizer (PFE) reported a 29% operational decline in third-quarter Comirnaty revenue, highlighting continued pressure on COVID vaccine demand.
- Moderna raised its 2026 revenue growth outlook to 15%–25%, but its elevated valuation makes taking some profits more attractive than buying additional shares.
What Happened?
Moderna (MRNA) stock gained approximately 9.8% over five trading sessions, closing at $250.83 on November 10 as stronger earnings and encouraging cancer treatment developments renewed investor optimism.
Shares rose 5.3% on November 6 and 5.8% on November 9 before declining 6.8% on November 10, highlighting continued volatility.
A major catalyst was Moderna’s collaboration with Merck (MRK) on intismeran, an experimental personalized cancer therapy.
Phase 3 results showed a 42% reduction in melanoma recurrence or death risk when intismeran was combined with Keytruda, compared with Keytruda alone.
A prespecified sensitivity analysis showed a 58% reduction in recurrence or death risk during the period following the initial six-month immunization regimen. Overall-survival data remain immature.
Meanwhile, Moderna reported third-quarter revenue of $1.3 billion, up 29% year over year, alongside GAAP diluted earnings of $0.38 per share.
CEO Stéphane Bancel said, “We delivered 29% revenue growth in the third quarter,” highlighting stronger commercial performance.
The results contrast with Pfizer (PFE), whose Comirnaty revenue declined 29% operationally.
However, Pfizer’s revenue excluding Comirnaty and Paxlovid grew 7% operationally, providing business diversification that Moderna is still developing.
Is Moderna Stock Undervalued or Overvalued?
Moderna appears overvalued at current levels, despite meaningful improvements in its financial outlook and cancer pipeline.
The company raised its 2026 revenue growth outlook to 15%–25%, compared with its previous expectation of up to 10%.
Earlier TIKR estimates projected revenue increasing from $1.94 billion in 2025 to $3.34 billion in 2028, although these forecasts predate the November earnings report.
Moderna also increased its expected year-end cash and investments to $8.1 billion–$8.3 billion.
However, the stronger financial position partly reflects approximately $2.6 billion in net convertible financing proceeds rather than operating cash generation alone.
Valuation remains the biggest concern.
As of November 2, TIKR data showed Moderna trading at approximately 46.2x forward sales, compared with its five-year historical average of 7.9x.
Although Moderna’s changing revenue base makes historical comparisons imperfect, the premium suggests substantial future oncology growth is already reflected in the stock price.
The bullish case remains meaningful. Early multiple myeloma data showed four confirmed responses among 11 evaluable patients receiving mRNA-2808, although the initial study remains small.
Updated findings are expected on December 12, offering another potential catalyst for Moderna’s oncology pipeline.
Moderna’s average analyst price target reached approximately $138 in the October 28 TIKR snapshot, substantially below its November 10 closing price of $250.83, although the older consensus may not reflect post-earnings revisions.
At $250.83 per share, Moderna’s valuation already reflects substantial optimism about its future commercial success.
For now, taking some profits appears more attractive than aggressively buying additional shares. Stronger clinical results and sustainable revenue growth could support further upside over the next 12 months, but Moderna’s premium valuation leaves limited room for setbacks.
So what is Moderna stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Moderna could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
